FDG Positron Emission Tomography (PET) for 9 Cancers (brain, cervical, small cell lung, ovarian, pancreatic, testicular, prostate, bladder and kidney

This meeting will focus on the oncologic indications of 2-[F-18] Fluoro-D-Glucose (FDG) positron emission tomography (PET) for nine cancers (brain, cervical, small cell lung, ovarian, pancreatic, testicular, prostate, bladder and kidney).  The panel will review the scientific evidence of the impact of PET as part of a management strategy to improve patient-centered outcomes.  The panel will also consider data generated in accordance with a prior national coverage determination to cover PET for specified cancers when additional data are prospectively collected.

August 1, 2008

August 14, 2008

August 15, 2008

August 27, 2008

September 26, 2008

Saty Satya-Murti, MD, FAAN, Acting Chair
Steve E. Phurrough, MD, MPA, Coverage and Analysis Group
Maria Ellis, Executive Secretary

7:30 - 8:00 AM

8:00 - 8:15 AM

8:15- 8:55 AM

8:55 - 9:40 AM

9:40 - 10:05 AM

10:05 - 10:30 AM

10:30 - 10:45 AM

10:45 -11:15 AM

******************************************************************************

Public attendees, who have contacted the executive secretary prior to the meeting, will address the panel and present information relevant to the agenda. Speakers are asked to state whether or not they have any financial involvement with manufacturers of any products being discussed or with their competitors and who funded their travel to this meeting.

******************************************************************************

11:15 - 11:35 AM

11:35 - 12:35 PM

12:35 -1:35 PM

1:35 - 2:45PM

2:45 - 3:30 PM

The Chairperson will ask each panel member to state his or her position on the voting questions

3:30 - 4:25 PM

4:25 - 4:30 PM

4:30 PM

Download Minutes [PDF, 20KB].

Use the following scale response for each of the questions below.

1. How confident are you that the evidence is adequate to conclude that FDG-PET imaging improves physician decision making when used for the following indications for each in these nine cancers?

2. How confident are you that the evidence is adequate to conclude that FDG-PET imaging improves patient oriented clinical outcomes when used for the following indications in each of these nine cancers?

3. How confident are you that these conclusions are generalizable to other cancers?

4. How confident are you that these conclusions are generalizable to non-research PET facilities in the general community?

5. How confident that these conclusions are generalizable to the Medicare beneficiary population?

Saty Satya-Murti, MD, FAAN, Acting Chair
Health Policy Consultant

I Craig Henderson, MD
Adjunct Professor of Medicine
University of California, San Francisco

Nora A. Janjan, MD
Professor, Dept of Radiation Oncology
University of Texas
M.D. Anderson Cancer Center

J. Leonard Lichtenfeld, MD
American Cancer Society

Andrew Sloan, MD
Staff Neurosurgeon
Department of Neurosurgery
University Hospitals of Cleveland

Michael Steinberg, MD
Professor and Chair
Department of Radiation Oncology
David Geffen School of Medicine at UCLA

Sean D. Sullivan, PhD
Professor of Pharmacy
Public Health and Medicine
Director
Pharmaceutical Outcomes and Research and Policy Program
University of Washington

Consumer Representative
Linda A. Bergthold, PhD
Independent Consultant & Researcher

Industry Representative
Peter Juhn, MD, MPH
President
Therapeutic Resource Centers
Medco Health Solutions, Inc.

Guest Panel Member
Richard L. Wahl, MD
Professor of Radiology and Oncology
Henry N. Wagner, Jr. Professor of  Nuclear Medicine
Director
Nuclear Medicine/PET Facility
Vice Chair
Radiology for Technology and Business  Development
Johns Hopkins University School of  Medicine

Guest Speakers
Bruce Hillner, MD
Professor
Department of Internal Medicine
MVC Campus
Virginia Commonwealth University

David Mankoff, MD, PhD
Seattle, Washington

CMS Liasion
Steve E. Phurrough, MD, MPH
Director
Coverage and Analysis Group

Executive Secretary
Maria A. Ellis